← Retour au Screener

Sector: Santé
Open in Terminal → LONN.SWLive chart · Key metrics · News · Smart money

Lonza Group

LONN.SW Large Cap

Healthcare · Diagnostics & Research

Mis à jour: Jun 18, 2026, 22:21 UTC

491,60 CHF
-0.34% aujourd'hui
52W: 454,60 CHF – 594,80 CHF
52W Low: 454,60 CHF Position: 26.4% 52W High: 594,80 CHF

Price Chart

Indicateurs clés

P/E Ratio
37.82x
Cours/Bénéfice
Forward P/E
22.55x
P/E prévisionnel
P/S Ratio
5.26x
Cours/Ventes
EV/EBITDA
18.04x
Valeur d'entreprise/EBITDA
Rend. dividende
1.02%
Rendement annuel du dividende
Cap. boursière
29,9 Md €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
-4.21%
Marge nette
ROE
10.48%
Rentabilité des capitaux propres
Beta
0.83
Sensibilité au marché
Positions vendeuses
% du flottant vendu à découvert
Volume moyen
167,197
Volume quotidien moyen

Valuation Analysis

Signal
Overvalued
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
23 analysts
Avg. Price Target
663,52 CHF
+34.97% upside
Target Range
550,00 CHF – 815,00 CHF

About the Company

Sector: Healthcare Industry: Diagnostics & Research Country: Switzerland Employees: 20,000 Exchange: EBS

Lonza Group en bref

Lonza Group (LONN.SW) is currently trading at 491,60 CHF with a market capitalization of 29,9 Md €. The trailing P/E ratio stands at 37.82x, with a forward P/E of 22.55x. The 52-week range spans from 454,60 CHF to 594,80 CHF ; the current price is 17.4% below the yearly high.

💰 Dividende

Lonza Group pays an annual dividend of 5,00 CHF per share, representing a yield of 1.02%. The payout ratio stands at 30.77%.

📊 Avis des analystes

23 analystes évaluent Lonza Group (LONN.SW) au consensus : None. L'objectif de cours moyen est de 663,52 CHF , soit un potentiel de +34.97% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 550,00 CHF à 815,00 CHF .

Lonza Group : la thèse d'investissement en détail

Lonza Group (LONN.SW) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The PEG ratio at 1.45 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

  • The forward P/E of 22.55x is meaningfully below the trailing 37.82x — analysts expect earnings to step up; the next earnings release is the test.
  • The analyst consensus price target implies 34.97% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts

Aucun point fort marquant dans les données actuelles.

Points faibles
  • Actuellement non rentable
  • Actuellement jugée surévaluée
  • Free cash flow négatif

Aperçu technique

MM 50 jours
495,39 CHF
-0.77% vs. cours
MM 200 jours
523,20 CHF
-6.04% vs. cours
Sous le plus haut 52s
−17.4%
594,80 CHF
Au-dessus du plus bas 52s
+8.1%
454,60 CHF

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

Risque de marché (Bêta)
0.83 · Proche du marché
Évolue moins que le marché global
Dette/Capitaux propres
58.74 · Modéré
Dette totale / capitaux propres

The data points to relatively defensive market behavior.

Trading Data

50-Day MA: 495,39 CHF
200-Day MA: 523,20 CHF
Volume: 176,898
Avg. Volume: 167,197
Short Ratio:
P/B Ratio: 4.34x
Debt/Equity: 58.74x
Free Cash Flow: -1 568 194 472 €

💵 Dividend Info

Dividend Yield
1.02%
Annual Rate
5,00 CHF
Payout Ratio
30.77%

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Lonza Group?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut